Skip to main content

Table 1 Characteristics of the patients enrolled in the study

From: Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

Patient characteristics N = 271
Age (years) 57 ± 10
Sex (male/female) 140/131
Body mass index 24 ± 3
Liver fibrosis (Stage 1/2/3/4) 71/82/60/6
Hepatitis activity (Grade 1/2/3) 164/49/6
rs 8099917 of IL28B (TT/TG/GG) 198/72/1
rs 738409 of PNPLA3 (CC/CG/GG) 81/136/54
HCV core amino acids 70 (arginine/glutamine) 150/91
Alanine aminotransferase (IU/L) 66 ± 55
Platelet count (10000 /mm3) 17 ± 6
Alpha fetoprotein (ng/mL) 11 ± 19
HOMA-IR 4.2 ± 8.4
Therapeutic outcome (SVR/relapse/NVR) 126/77/68
  1. : Mean ± standard deviation; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance; SVR, sustained virological response; NVR, null or partial virological response.